AirFluSal MDI: a new LABA/corticosteroid inhaler

AirFluSal MDI (salmeterol/fluticasone) is indicated for the regular treatment of asthma where use of a combination product containing a long-acting ß2-agonist and an inhaled corticosteroid is appropriate.

AirFluSal MDI (salmeterol/fluticasone) is available in two strengths: 25/125 microgram and 25/250 microgram.
AirFluSal MDI (salmeterol/fluticasone) is available in two strengths: 25/125 microgram and 25/250 microgram.

AirFluSal MDI can be used in patients from 18 years of age who are not adequately controlled with inhaled corticosteroids and an ‘as needed' inhaled short-acting β2-agonist, or who are already adequately controlled on both an inhaled corticosteroid and a long-acting β2-agonist. Two puffs are taken twice daily.

As AirFluSal MDI is not available in a 25/50 microgram presentation, patients requiring titration down to a dose of inhaled corticosteroid below 125 microgram must be switched to an alternative salmeterol/fluticasone inhaler.

AirFluSal MDI can be used with either the Volumatic or AeroChamber Plus spacer device.

The efficacy and safety of salmeterol and fluticasone for the treatment of asthma are well established. AirFluSal is already available as a breath-actuated dry-powder inhaler in the Forspiro device.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in